Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$298.71+4.90 (+1.67%)
Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –
Ligand Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ligand Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $25.52M, up 41.9% year over year. For fiscal 2025 it was $41.00M. Over ten years it grew 4.1% a year on average. The highest annual figure on record is $807.08M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.00M | – |
| FY2024 | Dec 31, 2024 | -$22.61M | -289.3% |
| FY2023 | Dec 31, 2023 | $11.94M | +293.2% |
| FY2022 | Dec 31, 2022 | $3.04M | -97.1% |
| FY2021 | Dec 31, 2021 | $103.85M | +176.9% |
| FY2020 | Dec 31, 2020 | $37.50M | -95.4% |
| FY2019 | Dec 31, 2019 | $807.08M | +392.9% |
| FY2018 | Dec 31, 2018 | $163.73M | +140.5% |
| FY2017 | Dec 31, 2017 | $68.08M | +55.1% |
| FY2016 | Dec 31, 2016 | $43.89M | +60.6% |
| FY2015 | Dec 31, 2015 | $27.33M | +39.2% |
| FY2014 | Dec 31, 2014 | $19.63M | +31.3% |
| FY2013 | Dec 31, 2013 | $14.94M | +7642.5% |
| FY2012 | Dec 31, 2012 | $193.00K | – |
| FY2011 | Dec 31, 2011 | -$878.00K | – |
| FY2010 | Dec 31, 2010 | -$29.30M | – |
| FY2009 | Dec 31, 2009 | -$9.97M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$15.76M | -128.5% |
| Q2 FY2026 | Jun 30, 2026 | $8.59M | +1.7% |
| Q1 FY2026 | Mar 31, 2026 | $17.37M | – |
| Q4 FY2025 | Dec 31, 2025 | $15.32M | – |
| Q3 FY2025 | Sep 30, 2025 | $55.39M | +1662.2% |
| Q2 FY2025 | Jun 30, 2025 | $8.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.22M | -1312.0% |
| Q4 FY2024 | Dec 31, 2024 | -$9.64M | – |
| Q3 FY2024 | Sep 30, 2024 | $3.14M | +2.1% |
| Q2 FY2024 | Jun 30, 2024 | -$19.10M | – |
| Q1 FY2024 | Mar 31, 2024 | $2.99M | -79.0% |
| Q4 FY2023 | Dec 31, 2023 | -$3.36M | – |
| Q3 FY2023 | Sep 30, 2023 | $3.08M | -75.1% |
| Q2 FY2023 | Jun 30, 2023 | -$1.98M | -122.9% |
| Q1 FY2023 | Mar 31, 2023 | $14.21M | +566.0% |
| Q4 FY2022 | Dec 31, 2022 | -$20.10M | -153.3% |
| Q3 FY2022 | Sep 30, 2022 | $12.34M | -21.4% |
| Q2 FY2022 | Jun 30, 2022 | $8.66M | -81.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.13M | -54.8% |
| Q4 FY2021 | Dec 31, 2021 | $37.69M | +64.8% |
| Q3 FY2021 | Sep 30, 2021 | $15.71M | +319.2% |
| Q2 FY2021 | Jun 30, 2021 | $45.74M | +544.2% |
| Q1 FY2021 | Mar 31, 2021 | $4.72M | +24.5% |
| Q4 FY2020 | Dec 31, 2020 | $22.87M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.75M | – |
| Q2 FY2020 | Jun 30, 2020 | $7.10M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.79M | -99.5% |
| Q4 FY2019 | Dec 31, 2019 | -$10.18M | -130.7% |
| Q3 FY2019 | Sep 30, 2019 | -$5.16M | -122.1% |
| Q2 FY2019 | Jun 30, 2019 | -$4.13M | -105.9% |
| Q1 FY2019 | Mar 31, 2019 | $826.54M | +2131.4% |
| Q4 FY2018 | Dec 31, 2018 | $33.15M | +16.9% |
| Q3 FY2018 | Sep 30, 2018 | $23.36M | +41.6% |
| Q2 FY2018 | Jun 30, 2018 | $70.18M | +439.2% |
| Q1 FY2018 | Mar 31, 2018 | $37.04M | +262.6% |
| Q4 FY2017 | Dec 31, 2017 | $28.35M | +46.5% |
| Q3 FY2017 | Sep 30, 2017 | $16.49M | – |
| Q2 FY2017 | Jun 30, 2017 | $13.02M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.22M | – |
| Q4 FY2016 | Dec 31, 2016 | $19.36M | – |
See a number that looks wrong?